Zomedica reports Q4 results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 13 2025
0mins
Should l Buy ?
Source: SeekingAlpha
Financial Performance: Zomedica reported a Q4 2024 revenue of $7.9 million, an 8% increase from Q4 2023, with significant growth in the Diagnostics segment driven by the TRUFORMA® product line; gross margin stood at 70.3%.
Net Loss and Cash Usage: The company experienced a net loss of $7.2 million for the quarter, a decrease from $22.4 million in the previous year, while total cash used was approximately $6.5 million, with adjusted non-GAAP operating cash burn at about $4.2 million.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
